Drug Discovery

Sub Categories on Drug Discovery

Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC, trial shows

Updated on: October 02,2025

Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC, trial shows

Updated on:October 02,2025

Novel spatial immune-based risk prediction platform can predict hepatocellular carcinoma recurrence

Updated on: April 22,2025

Novel spatial immune-based risk prediction platform can predict hepatocellular carcinoma recurrence

Updated on:April 22,2025

$Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC$

Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC

Updated on: October 03,2025

$Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC$

Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC

Updated on:October 03,2025

Cryo-EM reveals hidden mechanics of DNA replication and sheds new light on cancer target

Updated on: April 21,2025

Cryo-EM reveals hidden mechanics of DNA replication and sheds new light on cancer target

Updated on:April 21,2025

Weekly Update of Drug News-22/10/2025

On Oct 6 2025, AbbVie announced positive topline results from its Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) for upper limb essential tremor compared to placebo.

Updated on: October 22,2025

Weekly Update of Drug News-22/10/2025

On Oct 6 2025, AbbVie announced positive topline results from its Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) for upper limb essential tremor compared to placebo.

Updated on:October 22,2025